Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update

May 15, 2018

Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering

May 7, 2018

Heat Biologics, Inc. Prices $18,000,000 Public Offering

May 3, 2018

Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110

Apr 18, 2018

Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform

Mar 26, 2018

Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards

Mar 19, 2018

Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

Mar 14, 2018

Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam

Mar 13, 2018

Heat Biologics Adopts Stockholder Rights Plan

Mar 12, 2018

Heat Biologics Reports Fiscal Year 2017 Financial Results

Mar 2, 2018